20-2840825-C-G
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PVS1_StrongPM2PP3
The NM_022575.4(VPS16):c.51C>G(p.Tyr17Ter) variant causes a stop gained, splice region change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_022575.4 stop_gained, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VPS16 | NM_022575.4 | c.51C>G | p.Tyr17Ter | stop_gained, splice_region_variant | 1/24 | ENST00000380445.8 | NP_072097.2 | |
VPS16 | NM_080413.3 | c.51C>G | p.Tyr17Ter | stop_gained, splice_region_variant | 1/20 | NP_536338.1 | ||
PCED1A | NM_001271168.2 | c.-22+41G>C | intron_variant | NP_001258097.1 | ||||
PCED1A | XM_005260804.3 | c.-22+41G>C | intron_variant | XP_005260861.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
VPS16 | ENST00000380445.8 | c.51C>G | p.Tyr17Ter | stop_gained, splice_region_variant | 1/24 | 1 | NM_022575.4 | ENSP00000369810 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2022 | VPS16: PM2, PVS1:Moderate - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.